tirzepatide heart Weight-loss drug may lower failure deaths Tirzepatide Heart Health: Cardiovascular Benefits

514526, 2023, Wharton S et al

The SUSTAIN 6 trial showed that subcutaneous semaglutide reduced major adverse cardiovascular events by 26% in patients with type 2 diabetes and established cardiovascular disease (hazard ratio 0.74, 95% CI 0.58-0.95)

another barrier-enhancing mechanism is where Akkermansia induces Paneth cells to produce antimicrobial peptides, and SCFAs from intestinal mucin glycoproteins are absorbed in the colon as an energy source for colonic cells, inducing regulatory T cells and exerting anti-inflammatory effects (Reunanen et al., 2015

The results were announced today at the annual meeting of the American Diabetes Association and published in the New England Journal of Medicine

they make you feel very welcomed

Accordingly, postbiotics should be interpreted as adjunctive nutritional strategies rather than pharmacological alternatives to GLP-1 receptor agonists, with the most plausible utility during consolidation and maintenance phases aimed at improving metabolic context and supporting long-term weight-loss sustainability ( Figure 1 Importantly, accumulating preclinical evidence indicates that certain postbiotic preparations can attenuate weight gain, reduce adiposity, and activate thermogenic pathways, including brown adipose tissue signaling, particularly in high-fat dietfed rodent models